We critically evaluated clinical and laboratory metrics used to identify AD in MS patients (e.g., MRI, amyloid-β and tau protein identification, miRNA biomarker evaluation, cerebrospinal fluid analysis, vitamin levels, gut microbiota etc.).Conclusions: Future research should refine these diagnostic criteria and focus on enhancing screening and detection methods for AD in MS patients. This evidence concerns the gene MAPT and myeloid sarcoma.